Immunopharmacological reprogramming of innate immune memory in Alzheimer's disease: From microglial priming to therapeutic resilience.
It is argued that the next generation of AD therapeutics must move beyond target suppression toward the functional reprogramming of brain innate immunity, and a biomarker-guided, patient-stratified framework is proposed that integrates multimodal immunopharmacology, combining NLRP3 inhibition, TREM2 agonism, metabolic...